Cost-effectiveness of first-line hormone-therapies in chemonaïve castration-resistant prostate cancer Integrating the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) with the costs of drugs
Recenti Prog Med
.
2017 Jun;108(6):294-295.
doi: 10.1701/2715.27717.
[Article in Italian]
Authors
Jacopo Giuliani
1
,
Andrea Bonetti
1
Affiliation
1
Department of Oncology, Mater Salutis Hospital, Az. ULSS 9 Scaligera, Legnago (VR), Italy.
PMID:
28631778
DOI:
10.1701/2715.27717
No abstract available
Publication types
Letter
Comment